CSIMarket
 
Petvivo Holdings Inc   (NASDAQ: PETV)
Other Ticker:  
 
 
Price: $0.7000 $0.00 0.000%
Day's High: $0.7 Week Perf: 0.91 %
Day's Low: $ 0.63 30 Day Perf: -18.6 %
Volume (M): 16 52 Wk High: $ 0.98
Volume (M$): $ 11 52 Wk Avg: $0.60
Open: $0.70 52 Wk Low: $0.29



 Market Capitalization (Millions $) 14
 Shares Outstanding (Millions) 21
 Employees 9
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Petvivo Holdings Inc

We are based in suburban Minneapolis, Minnesota. We are a biomedical device company, which has been primarily engaged in the business of adapting human biomedical technology for products to be introduced for commercial sale in the veterinary market to treat pets and other animals suffering from arthritis and other afflictions. Our initial product, now being commercialized, is a medical device featuring injections of patented gel-like biomaterials into the afflicted body parts of pets or other animals suffering from osteoarthritis. The technology and manufacturing capability of this product was developed by Gel-Del and acquired by us for use to treat dogs, horses and other animals, but not for treatment of human afflictions. While working together pursuant to our initial license agreement, we and Gel-Del determined to combine our two companies through a stock exchange merger for the purpose of creating one combined entity utilizing Gel-Del technology to produce, market, and sell medical products based on Gel-Del technology for both animals and humans. After lengthy negotiations the parties entered into a definitive agreement for this merger, which resulted in the consummation of the merger in April, 2017.

We are an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and therapeutics for pets, based in Minneapolis, Minnesota. We operate in the $15 billion US veterinary care market that has grown at a CAGR of 6.4% over the past five years according to the American Pet Products Association. Despite the market size, veterinary clinics and hospitals have very few treatments and/or drugs for use in pets and other animals.

The role of pets in the family has greatly evolved in recent years. Many pet owners consider their pets an important member of the family. They are now willing to spend greater amounts of money on their pets to maintain their health and quality of life.

We intend to leverage investments already expended in the development of human therapeutics to commercialize treatments for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market earlier than the more stringently regulated veterinary pharmaceuticals or human therapeutics.

We are planning to aggressively launch our lead product Kush™ Canine in Q4 2017. Kush Canine is a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs. The Kush Canine device is made from natural components that are lubricious and cushioning to perform like cartilage for the treatment of pain and inflammation associated with osteoarthritis.

We believe that Kush Canine is a superior treatment that safely improves joint function. The reparative Kush Canine particles are lubricious, cushioning and long lasting. The spongy protein-based particles in Kush Canine mimic the composition and protective function of cartilage (i.e., providing both a slippery cushion and healing scaffolding). The Kush Canine particles protect the joint as an artificial cartilage.

Using industry sources we estimate osteoarthritis afflicts 20 million owned dogs in the United States and the European Union, making canine osteoarthritis a $2.3 billion market opportunity. See Johnston, Spencer A. “Osteoarthritis. Joint anatomy, physiology, and pathobiology.” The Veterinary clinics of North (1997):699-723;

Osteoarthritis is a condition with degenerating cartilage, creating joint stiffness from mechanical stress resulting in inflammation and pain. The lameness caused by osteoarthritis worsens with time from the ongoing loss of protective cushion and lubricity (i.e., loss of slippery padding). There is no current treatment for osteoarthritis, only palliative pain therapy or joint replacement. Non-steroidal anti-inflammatory drugs (NSAIDs) are used to alleviate the pain and inflammation, but long-term use has been shown to cause gastric problems. NSAIDs do not treat the cartilage degeneration issue to halt or slow the progression of the osteoarthritis condition.

We believe that our Kush Canine osteoarthritis treatment is far superior to current methodology of using NSAIDs. NSAIDs have many side effects, especially in canines, whereas the company’s injected Kush Canine treatment has been found to elicit no adverse side effects. Remarkably, Kush treated dogs show an increase in activity even after they no longer are receiving pain medication.

No special training is required for the administration of the Kush Canine devices. The treatment is injected into synovial joint space using standard intra-articular injection technique and multiple joints can be treated simultaneously. Kush Canine immediately treats effects of osteoarthritis with no special post treatment requirements.

Historically, drug sales represent up to 30% of revenues at a typical veterinary practice (Veterinary Practice News). Revenues and margins at veterinary practices are being eroded because online, big box and traditional pharmacies recently started filling veterinary prescriptions. Veterinary practices are looking for ways to replace the lost prescription revenues. Our treatments expand practice revenues & margins because they are veterinarian-administered. Our Kush Canine device is veterinarian-administered to expand practice revenues and margins. We believe that the increased revenues and margins provided by Kush Canine will accelerate its adoption rate and propel it forward as the standard of care for canine osteoarthritis.

Our product launch schedule includes at least two additional product releases in 2018. Our Kush Equine device for the treatment of equine lameness related to or impacting synovial joints is scheduled for launch in Q1 2018. The Kush Equine product has similar features and benefits as our Kush Canine device. In addition to being a treatment for osteoarthritis, the joint cushioning and lubricity effects of our devices have shown an ability to treat equine lameness that is due to navicular disease (a problem associated with misalignment of joints and bones in the hoof and digits). We anticipate launching our Kush Digital Cushion (DC) device for the treatment of navicular disease in 2018.

Based on a variety of industry sources we estimate that 1 million owned horses in the United Stated and European Union suffer from lameness and/or navicular disease each year, making the equine lameness and navicular disease market an annual opportunity worth $600 million. See Kane, Albert J., Josie Traub-Dargatz, Willard C. Losinger, and Lindsey P. Garber; “The occurrence and causes of lameness and laminitis in the US horse population” Proc Am Assoc Equine Pract. San Antonio (2000): 277-80; Seitzinger, Ann Hillberg, J. L. Traub-Dargatz, A. J. Kane, C. A. Kopral, P. S. Morley, L. P. Garber, W. C. Losinger, and G. W. Hill. “A comparison of the economic costs of equine lameness, colic, and equine protozoal myeloencephalitis (EPM).” In Proceedings, pp. 1048-1050. 2000; and Kilby, E. R. 10 CHAPTER, The Demographics of the U.S. Equine Population, The State of the Animals IV: 2007.



   Company Address: 5151 Edina Industrial Edina 55439 MN
   Company Phone Number: 405-6216   Stock Exchange / Ticker: NASDAQ PETV


Customers recorded net loss Customers recorded net loss



• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
PDCO        1.26% 
ELAN   -5.93%    
LLY   -3.33%    
MRK   -3.09%    
PFE   -3.86%    
ZOMDF        0.43% 
• View Complete Report
   



Petvivo Holdings Inc

Petvivo Holdings Inc's Top-Line Plummets by -61.571% in Fiscal Fourth Quarter of 2024

Petvivo Holdings Inc, a company in the medical equipment and supplies industry, recently released its financial results for the January to March 31, 2024 time-frame. The numbers showed a mixed performance, with a decrease in revenue and an increase in net loss compared to the previous year.
During this time period, Petvivo Holdings Inc reported a loss of $-0.13 per share, an improvement from the $-0.21 loss per share in the same quarter a year before. However, the company saw an increase in net loss, with a reported $-2.651 million loss compared to $-2.329 million in the previous year. Revenue also took a hit, with a sharp decline of -61.571% to $0.05 million from $0.13 million in the same quarter a year ago.
Additionally, Petvivo Holdings Inc pointed out a net loss of $-10.96 million for the fiscal year 2024, despite a slight improvement in loss per share from $-0.85 to $-0.78. The company's revenue for the fiscal year was reported as $0.97 million, a 5.62% increase from the previous yearOn the market side, Petvivo Holdings Inc stock performance has been less than stellar. The stock dropped -79.22% from a year ago, bringing the share price to just 25.36% during the Q of 2024. This places the stock at only 33.3% above its 52-week low, indicating a significant drop in value.
Overall, Petvivo Holdings Inc is facing challenges in terms of financial performance and stock value. The company will need to assess its strategies and make necessary adjustments to improve its profitability and market position in the coming quarters.

Petvivo Holdings Inc

Petvivo Holdings Inc. Soars to New Heights in Third Quarter Financial Results, Bucking Industry Trends

As a financial analyst for the , I have been closely following the recent financial results of Petvivo Holdings Inc for the third quarter of 2024. The numbers show a significant improvement in the company's performance compared to the previous year, with a decrease in loss per share, an increase in revenue, and a reduction in net loss.
One of the key highlights of the financial report is the substantial growth in revenue, which jumped by 16.816% to $0.60 million from $0.51 million in the same period last year. This growth is especially impressive when compared to the industry average, as most companies in the Medical Equipment & Supplies sector experienced a growth of only 5.58% during the same period.

Petvivo Holdings Inc

Petvivo Holdings Inc Experiences Widening Losses in Q2 2024 Amid Decrease in Orders


As an investor closely following Petvivo Holdings Inc, the recent financial results have presented a mixed bag of challenges and opportunities. In the second quarter of 2024, the company experienced lower turnover, resulting in a significant revenue decrease and a larger shortfall per share compared to the previous year. However, there were notable signs of potential growth and increasing demand within the Medical Equipment & Supplies industry.
One of the key financial indicators is the revenue, which decreased by -7.127% to $0.21 million year on year. This decline is concerning for Petvivo Holdings Inc, as it points to potential shortcomings in the company's ability to generate sales. Comparatively, the Medical Equipment & Supplies industry as a whole recorded a top-line rise in the same period, suggesting that Petvivo may be facing certain internal challenges.

Petvivo Holdings Inc

Medical Equipment & Supplies Company Faces Escalating Diminishing Returns in Q2 2023 Fiscal Period; Petvivo Holdings Inc. Reports Significant Revenue Growth but Increased Loss Per Share

Financial News Report: Petvivo Holdings Inc Reports Solid Revenue Growth but Increased Loss Per Share in Q2 2023
Petvivo Holdings Inc, a leading company in the pet healthcare industry, announced a remarkable rise in revenue of 101.435% year on year in the three-month period ending June 30, 2023. The company's revenue reached $0.12 million during this period. However, despite this impressive revenue growth, Petvivo Holdings Inc reported an increased loss per share at $-0.25 compared to the previous financial reporting period.
In the prior year, the company experienced a loss per share of $-0.21, showing an advancement in losses. Additionally, the revenue decreased by -6.701% from $0.13 million in the corresponding period. These figures indicate a decline in performance compared to the previous year.

Petvivo Holdings Inc

Stellar 126.468% Revenue Upsurge for Petvivo Holdings Inc Amid Recent Fiscal Period Despite Widening Deficit


Introduction:
Petvivo Holdings Inc, a Medical Equipment & Supplies company, recently released its financial results for the most recent fiscal period ending March 31, 2023. While the company showed a significant improvement in revenue, there are concerns regarding the widening deficit. This article aims to interpret the financial results and explore the possible implications for the company going forward.
Solid Revenue Improvement:
In the most recent fiscal period, Petvivo Holdings Inc recorded a remarkable revenue improvement of 126.468% year on year, reaching $0.13 million. This substantial growth signifies the company's ability to generate higher sales during the given period. However, it should be noted that this positive development follows a significant revenue decline of -75.378% in the previous reporting season.







Petvivo Holdings Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com